Clinical trials: Head and Neck Tumours
Nasopharyngeal Carcinoma
Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma
The purpose of this study is to determine the maximal tolerated dose (MTD) of re-irradiation using carbon ion radiotherapy (CIRT) along with concurrent chemotherapy in the treatment of locally recurrent nasopharyngeal cancer…
- Trial name
- NCT02801487
- Testing
- Carbon ion radiotherapy (CIRT), Cisplatin
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Thyroid Cancer
Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers
Determine the diagnostic value of 18F-PSMA-11 in patients with iodine refractory thyroid cancer.
- Trial name
- NCT05175404
- Testing
- PET/CT scan F18-PSMA-11
- Where
- Belgium
- Volunteers
- 8 people
- Sponsor
- University Hospital, Ghent
Esophageal Squamous Cell Carcinoma
Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
This is a prospective, single-arm, open-label，multi-center, phase II study, aiming to evaluate the efficacy and safety of AK104 combined with preoperative chemotherapy in patients with locally advanced ESCC.
- Trial name
- NCT05896787
- Testing
- AK104, nab-paclitaxel, carboplatin
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Head and Neck Squamous Cell Carcinoma (HNSCC)
Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
This study will evaluate the safety of adding nivolumab to several chemotherapy platforms with weekly cisplatin, high-dose cisplatin, cetuximab or radiation therapy alone.
- Trial name
- NCT02764593
- Testing
- Nivolumab, Cisplatin, Cetuximab
- Where
- 11 sites in United States
- Volunteers
- 40 people
- Sponsor
- RTOG Foundation, Inc.
Head and Neck Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Head and Neck Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer
- Trial name
- NCT01044433
- Testing
- lapatinib ditosylate, capecitabine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Esophageal Carcinoma
Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction
Background: Owing to controversial staging and classification of adenocarcinoma of the oesophagogastric junction (AOG) before surgery, the choice of appropriate surgical approach remains problematic.
- Trial name
- NCT01766986
- Volunteers
- 130 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Head and Neck Cancer (H&N), Cancer of the Head and Neck
Online Perioperative Education Program on Patient Satisfaction and Clinical Outcomes for Head and Neck Surgery
CareOrbit is a digital perioperative patient-education and care navigation platform developed by the St. Louis-based venture Total Orbit in collaboration with Washington University's CORTEX Business Incubator.
- Trial name
- NCT07848841
- Testing
- CareOrbit, Standard perioperative education
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Washington University School of Medicine
Head and Neck Squamous Cell Carcinoma
Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC
The purpose of this trial is to determine the efficacy of the immunotherapy with MVX-ONCO-1 in patients with advanced head and neck squamous cell carcinoma.
- Trial name
- NCT02999646
- Testing
- MVX-ONCO-1
- Where
- 4 sites in Switzerland
- Volunteers
- 16 people
- Sponsor
- Maxivax SA
Laryngeal Cancer
Nomograms to Precisely Predict Conditional Risk of Survival for Patients With Laryngeal Cancer
Advanced laryngeal squamous cell carcinoma (SCC) remains a highly morbid and fatal disease despite aggressive interventions. Mortality is high in this cohort: laryngeal cancer affects over 13 000 patients in the United States…
- Trial name
- NCT03747783
- Testing
- Radical Operation
- Where
- China
- Volunteers
- 400 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Head and Neck Carcinoma
Clinical Data Collection in Studying Clinical Factors Associated With Post-Surgery Chronic Opioid Use in Patients With Head and Neck Cancers
This trial studies the risk of developing disorders associated with chronic opioid use post-surgery in patients with head and neck cancers.
- Trial name
- NCT03888651
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- M.D. Anderson Cancer Center
Thyroid Cancer
Clinical Evaluation of Genetron TERT/BRAF PCR Kit in Thyroid Cancer Patients
The purpose of this trail is to evaluate the performance of Genetron TERT/BRAF PCR Kit in Thyriod Cancer patients using real-time PCR method.
- Trial name
- NCT05395429
- Where
- 4 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Genetron Health
Advanced Breast Carcinoma, Advanced Colon Carcinoma
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have…
- Conditions
- Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma
- Trial name
- NCT04704661
- Testing
- Biopsy Procedure, Biospecimen Collection, Ceralasertib
- Where
- 23 sites in United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors, Head and Neck Neoplasms
Trial to Determine Optimal Phase II Dose of the Oral Dual CAIX Inhibitor/ Radiosensitizer
This is a Phase I multicenter, open-label, dose-escalation study of DTP348. DTP 348 is an oral dual drug with two mechanisms of action: 1.
- Trial name
- NCT02216669
- Testing
- DTP348
- Where
- Netherlands
- Sponsor
- Maastricht Radiation Oncology
Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma
The purpose of study is to investigate the safety and efficacy of sequential immunotherapy with neoadjuvant chemoradiotherapy for esophageal cancer
- Trial name
- CRIS (NCT06303583)
- Testing
- paclitaxel, carboplatin, tislelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Qiu Guoqin
Gastric Adenocarcinoma, Oligometastasis
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
This phase II trial studies how well chemotherapy with or without radiation or surgery works in treating participants with esophageal or gastric cancer that has spread to less than 3 places in the body (oligometastatic).
- Conditions
- Gastric Adenocarcinoma, Oligometastasis, Stage IV Esophageal Adenocarcinoma AJCC v7, Stage IV Esophageal Cancer AJCC v7
- Trial name
- NCT03161522
- Testing
- Capecitabine, Chemotherapy, Conventional Surgery
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Cancer
BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy
Recent advancements in swallowable esophageal cell-collection devices (SECD) offer a safe, minimally invasive, accurate, and low-cost alternative to esophageal screening without the need for an upper endoscopy.
- Trial name
- BEST-RPP (NCT06335966)
- Testing
- Screening with swallowable esophageal cell-collection devices (SECD)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- OHSU Knight Cancer Institute
Lung Cancer, Breast Cancer
Clinical Validation of AI-Assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
The goal of this clinical trial is to evaluate performance and clinical applicability of AI-assisted radiotherapy contouring software (iCurveE) for thoracic organs at risk.
- Conditions
- Lung Cancer, Breast Cancer, Esophageal Cancer
- Trial name
- NCT05787522
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric Cancer, Renal Cell Carcinoma
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
- Trial name
- NCT05238883
- Testing
- HFB200301, Tislelizumab
- Where
- 10 sites in United States, Spain
- Volunteers
- 72 people
- Sponsor
- HiFiBiO Therapeutics
Recurrent Adenoid Cystic Carcinoma, Adenoid Cystic Carcinoma Metastatic
Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)
This is an open-label, investigator-initiated phase II clinical trial designed to evaluate the efficacy and safety of Sacituzumab Tirumotecan (sac-TMT) monotherapy in patients with recurrent or metastatic adenoid cystic carcinoma…
- Conditions
- Recurrent Adenoid Cystic Carcinoma, Adenoid Cystic Carcinoma Metastatic, Papillary Thyroid Carcinoma
- Trial name
- STRAP (NCT07521670)
- Testing
- Sacituzumab Tirumotecan
- Where
- 7 sites in Japan, Malaysia and 2 more
- Volunteers
- 68 people
- Sponsor
- National Cancer Centre, Singapore
Endoscopy, Digestive System, Esophageal Neoplasms
Endoscopic Submucosal Dissection in Upper Gastrointestinal Canal With HybridKnife
Endoscopic submucosal dissection (ESD) is a relatively new modality for the treatment of superficial gastrointestinal neoplasia and especially in the diagnosis and treatment of submucosal tumors.
- Conditions
- Endoscopy, Digestive System, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT01185483
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Odense University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.